Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating reiterated by equities research analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They presently have a $128.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential downside of 4.33% from the stock’s current price.

A number of other research analysts have also recently issued reports on SRPT. Royal Bank of Canada lifted their price objective on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Mizuho increased their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Barclays lifted their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Finally, BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target for the company. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $156.60.

Sarepta Therapeutics Trading Up 2.2 %

SRPT traded up $2.90 on Thursday, hitting $133.80. 1,218,794 shares of the company were exchanged, compared to its average volume of 1,003,298. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The firm has a fifty day simple moving average of $125.77 and a two-hundred day simple moving average of $110.56. The stock has a market capitalization of $12.65 billion, a PE ratio of -22.03 and a beta of 0.95. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.44) earnings per share. Sell-side analysts expect that Sarepta Therapeutics will post 2.13 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,815,030. The sale was disclosed in a filing with the SEC, which is available through this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the business. DMC Group LLC raised its holdings in Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after purchasing an additional 93 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Sarepta Therapeutics by 5.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after acquiring an additional 4,763 shares during the period. TD Asset Management Inc raised its stake in Sarepta Therapeutics by 377.7% during the 3rd quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after acquiring an additional 161,788 shares during the last quarter. Eagle Health Investments LP lifted its position in Sarepta Therapeutics by 79.0% during the 3rd quarter. Eagle Health Investments LP now owns 174,212 shares of the biotechnology company’s stock worth $21,118,000 after acquiring an additional 76,872 shares during the period. Finally, Hudson Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $206,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.